about
Scaffold/matrix attachment region elements interact with a p300-scaffold attachment factor A complex and are bound by acetylated nucleosomes.BLUEPRINT: mapping human blood cell epigenomesPartitioning and plasticity of repressive histone methylation states in mammalian chromatinCharacterization of plant proteins that interact with cowpea mosaic virus '60K' protein in the yeast two-hybrid system.Active and repressive chromatin are interspersed without spreading in an imprinted gene cluster in the mammalian genome.Platelet function is modified by common sequence variation in megakaryocyte super enhancersPML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity.Histone modification patterns associated with the human X chromosomeGlucocorticoid receptor and nuclear factor kappa-b affect three-dimensional chromatin organizationCandida albicans infection affords protection against reinfection via functional reprogramming of monocytes.The molecular signature of oncofusion proteins in acute myeloid leukemia.Genome-wide functions of PML-RARα in acute promyelocytic leukaemiaThe genome-wide molecular signature of transcription factors in leukemia.Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia.MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.Dual promoter usage as regulatory mechanism of let-7c expression in leukemic and solid tumors.AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.Genome-wide binding of transcription factors in inv(16) acute myeloid leukemia.β-Glucan Reverses the Epigenetic State of LPS-Induced Immunological Tolerance.Time-resolved analysis of DNA-protein interactions in living cells by UV laser pulses.Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity.Suv39h-dependent H3K9me3 marks intact retrotransposons and silences LINE elements in mouse embryonic stem cells.miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.The tetraspanin CD9 affords high-purity capture of all murine hematopoietic stem cells.BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells.The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.GFI1 is required for RUNX1/ETO positive acute myeloid leukemia.c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer.Dynamics of Transcription Regulation in Human Bone Marrow Myeloid Differentiation to Mature Blood NeutrophilsThe reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemiaE-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancerRUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLsChromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness PhenotypesmiR-194-5p/BCLAF1 deregulation in AML tumorigenesisBRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibitionCBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1CBFβ-SMMHC regulates ribosomal gene transcription and alters ribosome biogenesis
P50
Q24537237-F4313744-25E7-432A-A0AB-B118F12DF0D3Q28677161-D6F05391-3CBD-403F-9E1A-35BFD25C7DA9Q29614513-C34FD385-5C4B-4F92-A43C-ACBC4C652739Q30726011-3D2C7C0E-F798-4208-9957-5E1FC3A479ADQ33760054-94E82B17-DC9E-4EF3-8C9F-9DFD050E4882Q33906387-9073AB6E-D6E6-4EEE-9BB2-A12B01A97129Q34099047-307437E3-9B86-4571-8FCC-B6339BF5C281Q34460989-3E8E9389-3C4F-4511-9757-4B841A861747Q34481477-8825AE06-9BAB-44F1-989C-5EBB1CFCE4C1Q34683351-A5CF0049-07CA-44E9-BB81-FD6A14420C0FQ36335676-1F533845-9287-4C00-92E7-EB4FC9D56959Q37394444-DF3E5DD0-81AE-4EF4-BE82-4AE741385089Q37730254-64D50150-D13C-481C-A5E0-DB3A1F7FDAE0Q37829905-1FAAA28C-C574-4E32-BB0A-D8D5E7CF08FEQ38210679-3FEB917E-863A-4F2A-9DFA-360489903437Q38730980-7178B52F-E434-4595-AF3B-C681EECFB988Q38856290-D203ACCF-067C-42C9-B3AC-D04574630EBCQ39004166-1A0A62A4-E7E8-4FF6-96ED-820B958467F0Q39014664-26AF8CA7-BA07-48C6-952C-DC3D5459CD13Q39058012-268466B9-68D1-4E4D-94D5-8DDBE712B844Q40412447-1A42B985-DA2E-4CE4-A1D8-7B4EF7057A37Q40445242-0CFE27B9-D534-4F99-A8FB-33D3DB6D300FQ41718442-2DC2BC56-E582-436C-9666-47F3A317F0BEQ41725528-C712CC8C-DE45-48B4-81A5-EEB6B2543264Q42209064-9B80CCC5-2C3D-4F35-AD76-AE52C6E316B9Q44599122-3C7641A6-25C0-4188-BB31-D9994CEEC40BQ46525571-4C8E02DB-17B5-412A-B2EB-DB53968A0CCBQ47155915-0BFF8B99-909E-428D-87E7-516BA8257AE3Q51324654-4E8C6B9A-42D4-4731-A57F-492E56AB643DQ52718189-94A48CC0-4347-40BB-AEF0-4E814A358960Q53752852-07C4C472-3B22-47FD-98B3-484C2FBF7410Q57090260-6C3FDF60-5E65-44A2-84B9-AA955C46A442Q57090272-CC594F00-7C09-409D-B5FD-2346D041AC54Q58603744-9EDCFCB0-E97C-4C75-9226-BF3C71FF173CQ61801952-3A20AE68-C116-4FDA-8045-E0B3A1000A73Q61811556-1B02839D-552E-4A41-AF89-3106D80DC425Q63681545-7E07CF11-8E69-43D6-BB58-B38C538D8D5DQ64102049-13BD8924-1A82-4113-AD4C-5F08F0C0F3D3Q64112901-C586D039-BC1D-4F11-B1A0-C8DC151F5345Q89273845-FA1AAE5B-4F8A-4663-B015-033B665F761E
P50
description
researcher
@en
wetenschapper
@nl
name
Joost H A Martens
@en
Joost H A Martens
@nl
type
label
Joost H A Martens
@en
Joost H A Martens
@nl
prefLabel
Joost H A Martens
@en
Joost H A Martens
@nl
P106
P31
P496
0000-0003-2008-6537